The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab

被引：0
|
作者：
Grell, P.
Svoboda, M.
Fabian, P.
Radova, L.
Dziechciarkova, M.
Palacova, M.
Nenutil, R.
Hajduch, M.
Vyzula, R.
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Tomas Bata Univ Zlin, Zlin, Czech Republic
[3] Palacky Univ, CR-77147 Olomouc, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.1048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1048
引用
收藏
页数：1
相关论文
共 50 条
  • [31] SAFETY OF TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED HER2 POSITIVE ADVANCED BREAST CANCER
    Sakaguchi, Haruna
    Ishihara, Mikiya
    Sawaki, Akihiko
    Nagaharu, Keiki
    Oda, Hiroyasu
    Sugawara, Yumiko
    Tamaru, Satoshi
    Yamashita, Yoshiki
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2014, 25
  • [32] Characteristics and clinical outcome of patients with HR positive HER2 low metastatic breast cancer treated with CDK 4/6 inhibitors
    Cular, Katarina
    Kanceljak, Kristina
    Glas, Ana Magdalena
    Gudelj, Dora
    Krizic, Marija
    Popovic, Marina
    Plavetic, Natalija Dedic
    Sirotkovic-Skerlev, Maja
    Plestina, Stjepko
    Silovski, Tajana
    CANCER RESEARCH, 2024, 84 (09)
  • [33] Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival.
    Stemmler, L
    Kahlert, S
    Siekiera, W
    Untch, M
    Heinrich, B
    Heinemann, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 131S - 131S
  • [34] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [35] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
  • [36] Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+metastatic breast cancer
    Gajria, D.
    King, T.
    Pannu, H.
    Sakr, R.
    Modi, S.
    Drullinsky, P.
    Syldor, A.
    Path, S.
    Seidman, A.
    Norton, L.
    Rosen, N.
    Hudis, C.
    Chandarlapaty, S.
    CANCER RESEARCH, 2012, 72
  • [37] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] HER2 ECD-positive metastatic breast cancer treated with gemcitabine, paclitaxel plus trastuzumab (GTH)
    Colomer, R
    Mayordomo, JI
    Calvo, L
    Hornedo, J
    Carabantes, F
    Gil, M
    Cortes-Funes, H
    Martin, B
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S127 - S128
  • [39] Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
    Caroline Rönnlund
    Emmanouil G. Sifakis
    Caroline Schagerholm
    Qiao Yang
    Emelie Karlsson
    Xinsong Chen
    Theodoros Foukakis
    Jodi Weidler
    Michael Bates
    Irma Fredriksson
    Stephanie Robertson
    Johan Hartman
    Breast Cancer Research, 26
  • [40] Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
    Ronnlund, Caroline
    Sifakis, Emmanouil G.
    Schagerholm, Caroline
    Yang, Qiao
    Karlsson, Emelie
    Chen, Xinsong
    Foukakis, Theodoros
    Weidler, Jodi
    Bates, Michael
    Fredriksson, Irma
    Robertson, Stephanie
    Hartman, Johan
    BREAST CANCER RESEARCH, 2024, 26 (01)
12345